Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients

Next Previous
X
Search
Trial Profile

Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 25 Oct 2020 Results (n=1710) comparing week 96 results of phase and phase 3 studies (P018, P021 & P007), presented at the IDWeek 2020.
    • 08 Oct 2020 Results (n=1710) of post hoc and pooled analysis from NCT01632345; NCT02275780 and NCT02403674 evaluating changes in weight and body mass index in adults with HIV-1 at 1 and 2 years after starting an antiretroviral regimen, published in the AIDS
    • 23 May 2019 Results of prespecified integrated safety analysis using 3 double blind trials (NCT01632345, NCT02275780 and NCT02403674) published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top